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Main results
82 partners became infected with HIV-1 during the study. Both TDF and TDF-FTC reduced risk for HIV-1 transmission compared with placebo (Table) . TDF and TDF-FTC groups did not differ (P = 0.23). Groups did not differ for adverse events or death (P > 0.24 for all).
Conclusion
Preexposure prophylaxis with oral antiretroviral tenofovir disoproxil fumarate (TDF) and TDF plus emtricitabine reduced transmission of HIV-1 to seronegative partners in serodiscordant heterosexual couples. 
*

Commentary
Primary prophylaxis with oral antiretroviral therapy to prevent acquisition of HIV infection (or PrEP) works. Baeten and colleagues showed that administration of daily TDF, with or without FTC, to uninfected heterosexual partners of HIV-1-infected persons achieved a 67% to 75% relative reduction in the incidence of HIV-1 infection compared with persons receiving placebo, and that the incidence was reduced in both men and women. Efficacy correlated with drug adherence: Of 29 persons in the TDF or TDF-FTC groups who seroconverted, only 31% had detectable TDF levels in plasma samples obtained at the seroconversion visit compared with 82% of 902 samples from a random subgroup of 198 participants who remained seronegative. An earlier study that randomly assigned HIV-seronegative men who have sex with men to receive either daily TDF-FTC or placebo found a 44% reduction in incident HIV infection in the TDF-FTC group (1) . In a subgroup analysis of the TDF-FTC group, ≥ 1 of the study drug components was found in only 3 of 34 participants (9%) who seroconverted compared with 22 of 43 participants (51%) who remained seronegative (1). Adherence was a critical component of prophylaxis efficacy in both studies; the effect of adherence in nonstudy settings is likely to be even greater. In July 2012, the US Food and Drug Administration (FDA) approved the use of TDF-FTC as the first drug to reduce the risk for HIV infection in uninfected individuals at high risk (2) . The FDA required the manufacturer to develop a strategy to manage the risks associated with administration of PrEP. Still, the burden of oversight for the appropriate use of PrEP will fall to the clinician. Challenges to the safe administration of PrEP include ensuring adherence; continuing such other preventive strategies as safe sex practices, risk reduction counseling, and regular HIV testing; and preventing administration of TDF-FTC to seropositive individuals.
